User:Mr. Ibrahem/Lenalidomide

Mr. Ibrahem/Lenalidomide
Clinical data
Pronunciation	/ˌlɛnəˈlɪdoʊmaɪd/
Trade names	Revlimid, Linamide, others
AHFS/Drugs.com	Monograph
MedlinePlus	a608001
License data	EU EMA: by INN; US DailyMed: Lenalidomide;
Pregnancy; category	AU: X (High risk); ;
Routes of; administration	By mouth (capsules)
Drug class	Thalidomide analogue
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	Undetermined
Protein binding	30%
Metabolism	Undetermined
Elimination half-life	3 hours
Excretion	Kidney (67% unchanged)
Identifiers
	IUPAC name (RS)-3-(4-Amino-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;
Chemical and physical data
Formula	C13H13N3O3
Molar mass	259.265 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES O=C1NC(=O)CCC1N3C(=O)c2cccc(c2C3)N;
	InChI InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18) ; Key:GOTYRUGSSMKFNF-UHFFFAOYSA-N ;
	(verify)

Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS).^[2] For MM it is used after at least one other treatment and generally together with dexamethasone.^[2] It is taken by mouth.^[2]

Common side effects include diarrhea, itchiness, joint pain, fever, headache, and trouble sleeping.^[2] Severe side effects may include low blood platelets, low white blood cells, and blood clots.^[2] Use during pregnancy may harm the baby.^[2] The dose may need to be adjusted in people with kidney problems.^[2] It has a chemical structure similar to thalidomide but has a different mechanism of action.^[1]^[2] How it works is not entirely clear as of 2019.^[2]

Lenalidomide was approved for medical use in the United States in 2005.^[2] It is on the World Health Organization's List of Essential Medicines.^[4] In the United States it costs about US$16,000 to US$21,000 per month as of 2019.^[5] In the United Kingdom this amount costs the NHS about £3,400 to 4,400.^[6]

References edit

^ ^a ^b "DailyMed - Revlimid- lenalidomide capsule". dailymed.nlm.nih.gov. Archived from the original on 16 February 2020. Retrieved 27 October 2019.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l "Lenalidomide Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2016. Retrieved 27 October 2019.
^ "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 9 August 2020. Retrieved 11 September 2020.
^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
^ "Revlimid Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 27 October 2019. Retrieved 27 October 2019.
^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 935. ISBN 9780857113382.

[PI2019-1] "DailyMed - Revlimid- lenalidomide capsule". dailymed.nlm.nih.gov. Archived from the original on 16 February 2020. Retrieved 27 October 2019.

[AHFS2019-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l "Lenalidomide Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2016. Retrieved 27 October 2019.

[who-3] "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 9 August 2020. Retrieved 11 September 2020.

[WHO21st-4] World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[5] "Revlimid Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 27 October 2019. Retrieved 27 October 2019.

[BNF76-6] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 935. ISBN 9780857113382.

[1]

[2]

[4]

[5]

[6]